Form 4 Filing for CRISPR Therapeutics AG

On September 22, 2026, James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reported several transactions involving the company's common shares. Kasinger acquired 10,400 shares under the 2026 Employee Stock Purchase Plan at a price of $13.62 per share, increasing his post-transaction holdings to 105,184 shares. Concurrently, he disposed of 10,400 shares at a weighted average price of $60.2365 per share, with individual sales ranging from $60.00 to $60.65. These sales were executed under a Rule 10b5-1 trading plan. Additionally, Kasinger exercised a stock option to acquire 10,400 common shares, which had an exercise price of $13.62, leaving him with 83,232 shares post-transaction. The option grant was dated May 31, 2017, with a vesting schedule detailed in footnote F4.